A. Franceschino

发表

Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib

C. Gambacorti-Passerini, S. Assouline, A. Franceschino, 2008, Haematologica.

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

C. Crawley, D. Marin, J. Goldman, 2003, Leukemia.

Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients

M. Varella‐Garcia, F. Andreoni, C. Gambacorti-Passerini, 2005, Leukemia.

Human Cancer Biology Benign Mesenchymal Stromal Cells in Human Sarcomas

A. Moreira, R. Maki, J. Healey, 2010 .

Benign Mesenchymal Stromal Cells in Human Sarcomas

A. Moreira, R. Maki, J. Healey, 2010, Clinical Cancer Research.

The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.

F. Andreoni, C. Gambacorti-Passerini, R. Piazza, 2006, Blood cells, molecules & diseases.

Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.

R. Piazza, E. Pogliani, C. Gambacorti Passerini, 2006, Haematologica.

Imatinib concentrations in human milk.

M. Zucchetti, M. D’Incalci, C. Gambacorti-Passerini, 2007, Blood.

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

R. Piazza, E. Pogliani, G. Corneo, 2007, Nature Medicine.

Reasons to Eliminate Umbilical Cord Blood Units before Cryopreservation

A. Calogero, C. Pafumi, P. Giardina, 2001, Hematology.

Corrigendum: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

C. Gambacorti-Passerini, R. Piazza, E. Pogliani, 2007, Nature Medicine.